New beta-lactam-beta-lactamase inhibitor combinations in clinical development.

Article Details

Citation

Shlaes DM

New beta-lactam-beta-lactamase inhibitor combinations in clinical development.

Ann N Y Acad Sci. 2013 Jan;1277:105-14. doi: 10.1111/nyas.12010.

PubMed ID
23346860 [ View in PubMed
]
Abstract

Tazobactam was the most recent beta-lactamase inhibitor to be approved in 1993. Since the approval of piperacillin-tazobactam, the complexity of beta-lactamase-mediated resistance among Gram-negative bacilli has increased enormously. After more than 20 years since the first such combination, amoxicillin-clavulanic acid, was approved, several new beta-lactam-beta-lactamase inhibitor combinations have reached late-stage (phase II and beyond) clinical trials. These include ceftolozane-tazobactam (2:1, ratios of beta-lactam to beta-lactamase inhibitor in parentheses), ceftazidime-avibactam (4:1), ceftaroline-avibactam (1:1), and imipenem-cilastatin-MK-7655 (2:2:1 and 4:4:1). Avibactam and MK-7655 are diazabicyclooctane (DABCO) inhibitors and thus not beta-lactams themselves; they include class A carbapenemases and class C enzymes within their spectra of activity. Ceftolozane is an antipseudomonal cephalosporin, and tazobactam is used to protect it against extended spectrum beta-lactamases to which it is labile. Additional novel combinations are in preclinical development. This review will focus on the biochemistry, antimicrobial activity, pharmacodynamics, and clinical development of these novel combinations.

DrugBank Data that Cites this Article

Drugs